Created: February 20, 2025 • Updated: September 9, 2025
Juan Roman
United States
Juan Roman's deliberate insider trading undermines ethical standards, violates company policies, and damages market integrity. His misconduct has led to significant legal and reputational consequences.
1.5/5
Trust Score
Composite score based on public data signals and verifiability indicators.
2
Red Flags
The dossier on Juan Roman has been compiled using publicly available sources including court records, regulatory filings, corporate registries, archived media reports, and other verifiable documents. Research is conducted in collaboration with journalists, OSINT analysts, researchers, and citizen contributors.
The information presented is provided for informational and research purposes only and does not constitute legal advice or a legal determination regarding Juan Roman. We welcome credible evidence, corrections, or additional documentation that may help improve the accuracy and completeness of this record.
Juan Roman, a former Senior Director at Acceleron Pharma, flagrantly disregarded his fiduciary duties by engaging in insider trading. Despite being privy to confidential information about Acceleron’s drug developments, he exploited this knowledge for personal gain. His actions not only breached ethical norms but also undermined the trust placed in corporate executives.
Violation of Company Policies: Roman’s conduct was in direct violation of Acceleron’s internal policies, which included mandatory blackout periods preventing employees from trading company securities. His deliberate bypassing of these restrictions highlights a blatant disregard for corporate governance and compliance protocols.
Financial Misappropriation: By trading on nonpublic information, Roman secured illicit profits, thereby distorting market fairness. Such actions contribute to market inefficiencies and erode investor confidence, as they create an uneven playing field for legitimate investors.
Legal Consequences: The Securities and Exchange Commission (SEC) charged Roman with violating federal securities laws, seeking remedies that include disgorgement of ill-gotten gains, civil penalties, and a permanent bar from serving as an officer or director of any public company. These legal repercussions underscore the severity of his misconduct and serve as a deterrent against similar future violations.
Damage to Corporate Reputation: Roman’s actions tarnish not only his personal reputation but also that of Acceleron Pharma. Such scandals can lead to a loss of stakeholder trust, potential declines in stock value, and increased scrutiny from regulators and the public.
Compliance and Regulatory Intel for Juan Roman
| Risk Category | Assessment Question | Status |
|---|---|---|
| Liabilities | Does have any significant outstanding liabilities that may pose financial risks? | Definitely Yes |
| Undisclosed Relations | Are there undisclosed business relationships or affiliations linked to ? | Not Known |
| Sanctions or Watchlist Matches | Is listed on any international sanctions or compliance watchlists? | Not Known |
| Criminal Record | Does have a record of criminal activity or related investigations? | Definitely Yes |
| Civil Lawsuits | Are there civil lawsuits, past or present, involving ? | Definitely Yes |
| Regulatory Violations | Has faced regulatory violations or penalties? | Not Known |
| Bankruptcy History | Has filed for bankruptcy or been involved in any bankruptcy proceedings? | Definitely Yes |
| Adverse Media Mentions | Have there been significant adverse media mentions related to ? | Not Known |
| Negative Customer Reviews | Are there negative reviews or complaints from customers or clients about ? | Potentially No |
| High-Risk Jurisdiction Exposure | Does operate within or have exposure to high-risk jurisdictions? | Not Known |
| Ongoing Investigations | Is currently subject to any ongoing investigations? | Definitely Yes |
| Fraud or Scam Allegations | Have there been fraud or scam allegations involving ? | Definitely Yes |
| Reputational Risk Incidents | Have there been incidents significantly impacting ’s reputation? | Definitely Yes |
| High-Risk Business Activities | Is engaged in any high-risk business activities? | Potentially No |
Our Research Methodology for Juan Roman
Sources, verification, and research standards behind our reports.
Public Records Review
LegalObserver analyzes verifiable public records including court filings, regulatory disclosures, enforcement actions, corporate registries, and government databases. Each entry links to original documentation whenever possible to allow independent verification.
Court Filings & Litigation
We examine civil, criminal, and regulatory proceedings involving the subject. This includes lawsuits, judgments, settlements, injunctions, and other documented litigation history obtained from court databases and legal archives.
Corporate & Ownership Data
Corporate filings, director records, shareholder disclosures, and beneficial ownership data are reviewed to identify business affiliations, control structures, and related entities.
Regulatory & Compliance Records
We review enforcement notices, regulatory actions, sanctions listings, compliance warnings, and disciplinary records issued by financial, governmental, and professional authorities.
Media & Archive Research
Coverage from established news organizations, investigative journalism outlets, and archived publications is analyzed to document historical reporting and public narratives associated with the subject.
OSINT Intelligence
Open-source intelligence techniques are used to gather and cross-reference information from publicly accessible sources including corporate registries, official disclosures, archived webpages, and investigative databases.
Censorship & Takedown Monitoring
LegalObserver documents verified attempts to suppress or remove public information, including questionable copyright claims, takedown notices, or legal threats directed at publishers or archives.
Risk & Context Analysis
All verified information is evaluated for context and relevance. The goal is to present documented facts, legal developments, and historical records in a structured format that helps readers understand potential legal, reputational, or compliance risks.
Internet Archives and Screenshots – Juan Roman
About us
- LegalObserver publishes investigative dossiers compiled from publicly available sources including court records, regulatory filings, corporate registries, and archived media reports.
- Our research is conducted in collaboration with journalists, OSINT analysts, researchers, and citizen contributors who review and cross-reference verifiable information.
- We publish information for research and public interest purposes and welcome credible evidence, corrections, or additional documentation that may improve the accuracy of our records.
Source of Information
- 1 SEC Securities and Exchange Commission v. Juan Roman, No. 1:23-cv-11470 (D. Mass. filed June 30, 2023) Retrieved 30/06/2023
- 2 SEC 1 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS Retrieved 30/06/2023
- 3 JD SUPRA SEC and DOJ Go On An Insider-Trading Enforcement Spree Retrieved 10/07/2023
- 4 Alpha Beta Stock SEC Charges Former Acceleron Pharma Director Juan Roman with Insider Trading Settles for Over $200000 Retrieved 21/07/2023
Access the Full Intelligence Network
Create a free account to unlock extended dossiers, investigation updates, archive records, and community intelligence. Upgrade for advanced research tools, alerts, and premium investigative reports.
Upgrade to Pro for $10/month
Jon Garnett
Australia
Intel Reports
6
Trust Score
1.8
Ankur Agarwal
Dubai, United Arab Emirates
Intel Reports
1
Trust Score
1.9
User Feedback
Public feedback and intelligence submitted by readers and researchers
1.7
Average Ratings
Based on 3 Ratings
Add Feedback
Your feedback helps improve our platform and service
Roman made his choices, and they were all selfish. He deserves far worse than just a fine.
This guy didn’t just cheat the system; he betrayed his own company and colleagues for personal gain.
Betraying shareholders, the company, and investors? He should be banned from finance permanently.really big scammmer for everyone